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Abstract
Background: The studies on heart rate variability (HRV), a key predictor of all-cause mortality, 
in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 
mutations.
Methods: Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have  
had a FBN1 gene mutation. Short electrocardiography records were taken in the supine posi-
tion and during orthostatic tests. The control group consisted of 30 apparently healthy non-
athletes matched by age and gender.
Results: Heart rates in MS patients with the FBN1 mutation were increased in both the su-
pine position and orthostatic test (p < 0.001). Most of the time-domain (standard deviation, 
pNN50) and frequency-domain (total power, very low, low, and high frequency) parameters of 
HRV were significantly reduced in the MS patients (p < 0.001).
Conclusions: A marked decrease in HRV, documented in the study, may be an important clini-
cal feature in MS patients with confirmed FBN1 gene mutations. (Cardiol J 2016; 23, 1: 23–33)
Key words: Marfan syndrome, FBN1 mutation, heart rate variability, heart rate, 
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Introduction
Marfan syndrome (MS), being a relatively 
common genetic disease with an estimated popula-
tion incidence 2–3/10,000, raises serious concerns 
due to aortal dilation that significantly increases 
risk of dissection, with potentially life threaten-
ing complications often developing at a young age 
[1, 2]. Other major clinical manifestations include 
typical abnormalities of the skeleton, eyes and 
a number of other health problems [2, 3].
The molecular basis of this disease is the 
mutation of the FBN1 gene, encoding for the syn-
thesis of fibrillin 1, a protein providing important 
structural function in the extracellular matrix. In 
addition, it participates in signaling pathways by 
transforming factor beta (TGF-b) binding domains. 
Therefore, altered function of FBN1 in MS leads to 
both structural (mucoid degeneration and degrada-
tion of the extracellular matrix) and functional (ac-
tivation of the TGF-b pathway) consequences [2]. 
Defective FBN1 structure is associated with activa-
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tion of proteases in response to gradual functional 
tissue damage together with TGF-b-related repara-
tive responses leading occasionally to induction of 
apoptosis in cells. Also, focal sclerosis create the 
medium for development of clinical manifestations 
[4]. Besides, the strategy to block TGF-b signal-
ing ameliorated myocardial fibrosis and diastolic 
dysfunction in a model study [5], confirming the 
deteriorating effects of excessive TGF-b.
Despite the wide presence of the FBN1 pro-
tein in various tissues, the noticeable changes 
develop primarily in loci where the function of this 
protein is critical — aorta, eyes, skeleton, visceral 
layer of pleura etc. [1–3]. Naturally, the attention 
of investigators is focused mainly on the major 
pathological changes, while many other aspects 
of the disease remain unstudied. In particular the 
heart rhythm peculiarities and abnormalities in 
MS are less studied. In fact, these changes seem 
to be clinically not as important as aortal dissection 
or lens ectopy. However, proper understanding of 
heart rhythm changes eventually appearing in MS 
patients may improve the diagnostics and potential 
risk assessment. Finally, it could be valuable in the 
search of long-term follow-up and the criteria for 
the evaluation of management efficiency in this 
group of patients.
The most significant heart rhythm abnormali-
ties previously reported in MS are interval PQ pro-
longation (decreased atrioventricular conductivity) 
and ventricular extrasystoles [6]. Since 1996, when 
standards of heart rate variability (HRV) meas-
urements and interpretation were published [7], 
dramatic growth of interest in the method has been 
observed. The consensus exists that the param-
eters of HRV reflect the activities of sympathetic 
and parasympathetic branches of the autonomic 
nervous system. Among the most important as-
sociations of reduced HRV reported to the date 
are all cause mortality, risk of fatal arrhythmias, 
and many others [8]. In addition, the relationships 
of HRV to important inflammatory parameters as 
well as insulin resistance, oxidative stress and 
dyslipidemia have been established [9, 10].
To our best knowledge, to date there have 
been no reports of HRV parameters in MS patients 
derived from the short electrocardiography (ECG) 
records taken in laboratory conditions. The only 
known study of Holter heart monitoring of MS pa-
tients which includes HRV parameters has recently 
been published [11]. However, in the paper, there 
is a lack of HRV description. The other study from 
this group includes HRV data from 24 h monitor-
ing. However, this paper focused on stratification 
of sudden cardiac death in MS, and the HRV was 
compared between two subgroups of patients 
without indication if it was high or low compared 
to healthy subjects [12]. There are also two papers 
reporting increased fatigue and orthostatic intol-
erance in MS patients. Authors suggest that it is 
possibly associated with increased body height and 
structural abnormalities of blood vessels, while 
autonomic function or HRV was not assessed [13, 
14]. Therefore, the aim of this work is to study the 
HRV parameters in a cohort of MS patients with 
confirmed FBN1 mutations and to compare them 
to an age and gender matched control group. In 
addition, an effort has been made to analyze the 
role of possible important factors contributing to 
the changes in HRV parameters in MS patients.
Methods
Patients and clinical data
A total number of 19 MS patients were re-
cruited for this study (case-control design) from 
2010 to 2014. The median age was 30.7 ± 1.6 
(range 23–42) years. All patients met strict diag-
nostic criteria for MS based on the original revised 
Ghent nosology [3] and respective Systemic score 
was determined by means of an online tool at http:// 
//www.marfan.org/dx/score. All the patients under-
went physical examination, routine clinical tests 
and echocardiography. Height was measured with 
a standardized stadiometer, patients were weighed 
on electronic scales (OMRON Corporation, Kyoto, 
Japan), and body mass index (BMI) was calculated. 
Clinical Systemic scores were above 7 in majority 
of MS patients 11 of the MS patients (57.9%). Nine 
(47.4%) patients had aortic root/valve-replacing 
surgery (Bentall procedure) in the past. Patients 
with sinus rhythm were included in the study, while 
any heart rhythm disorders possibly significantly 
distorting HRV evaluation (e.g. atrial fibrillation; 
multiple extrasystoles, more than 1/min, atrio-
ventricular blocks of second and third degree etc.) 
were excluded from the study. We did not find 
any clinically significant heart conduction abnor-
malities like PR interval prolongation over 0.2 s, or 
QT interval prolongation in MS patients and healthy 
subjects involved in the study. While recruiting 
1 MS patient was observed with frequent ven-
tricular extrasystoles, therefore, his results were 
excluded from the database. Standard treatment of 
MS patients included losartan 100.0 mg twice daily, 
however most of the patients were not taking this 
drugs or took it occasionally before participation 
in the study. Patients after Bentall surgery were 
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taking warfarin in addition to standard treatment. 
The control group consisted of 30 apparently 
healthy non-athletes matched by age (range 20–40, 
mean 29.3 ± 1.0 years) and gender distribution 
(males/females ratio 12/7 in MS group vs. 20/10 
in control group). The Ethics Committee of Lviv 
National Medical University approved the clinical 
and genetic program for MS. A written informed 
consent form was obtained from all patients. Data 
on familial and de novo cases was derived from 
family screening and tracing of clinical records.
Genetic studies
A Haploplex (Agilent Technologies, Santa 
Clara, California, USA) assay was used for enrich-
ment of 12 TAA genes and the samples sequenced 
with next generation sequencing on a Miseq 
(Illumina, San Diego, California USA). Subse-
quently, the putative mutations were confirmed 
with Sanger sequencing on an ABI sequencer (Life 
Technologies, Carlsbad, California, USA). Patients 
were screened for FBN1, TGFBR1, TGFBR2, 
NOTCH1, FLNA, EFEMP2, SLC2A10, MYLK, 
MYH11, COL3A1, SMAD3 and ACTA2 genes. 
Genetic testing was performed in the Center of 
Medical Genetics, Antwerp, Belgium.
In the studied cohort of MS patients, we did 
not identify any other mutations than FBN1, which 
provided relative homogeneity of the group in 
terms of presence of identical biochemical changes 
caused by specific molecular defect. The other 
3 patients had neither FBN1 nor any other muta-
tions mentioned above, according to the screening 
results.
Study of HRV
During quiet wakefulness in the morning 
hours, not less than 24 h after the last significant 
physical exercise, the short-time records of ECG 
were taken. A computer electrocardiograph VNS-
-Micro (Neurosoft®, Ivanovo, Russia) was used for 
ECG records. After 20 min of rest, studied sub-
jects were asked to stay supine quietly for 5 min 
to ensure quasi-stationary condition HRV re-
cording; afterwards they were asked to stand up 
rapidly and remain in the standing position for 
6 min — active orthostatic test (OT). RR intervals 
were determined with a sampling frequency of 
2.0 kHz and were analyzed with Poly-Spectrum 
(Neurosoft®, Ivanovo, Russia) software designed in 
line with HRV standards [7]. The time-domain pa-
rameters — standard deviation of normal RR inter-
vals (SDNN), the square root of the mean squared 
differences of successive RR intervals (RMSSD), 
and percentage of differences between adjacent 
normal RR intervals exceeding 50 ms (pNN50) 
were determined. The power spectral analysis was 
performed sequentially with a fast Fourier transfor-
mation. The following frequency-domain variables 
were studied: total power (TP, 0.01–0.40 Hz), 
high frequency power (HF, 0.15–0.40 Hz), low 
frequency power (LF, 0.04–0.15 Hz), and very low 
frequency power (VLF, 0.01–0.04 Hz). Occasional 
extrasystoles (not more than 1/min) as well as ar-
tifacts were detected ad oculus by an experienced 
physician and removed manually from the analysis. 
Extrasystoles were excluded from the analysis 
together with consecutive compensatory pause.
Short-term 5 min records of ECG for HRV 
analysis, despite some limitations, can be per-
formed in strict laboratory conditions and provide 
nearly stationary (quasi-stationary) heart rate 
(HR), which is sufficient for accurate determination 
of HRV parameters according to the standards, in 
particular HF and LF spectral power. Short records, 
in fact, are suboptimal for SDNN and VLF determi-
nation, however in a 24-h monitoring, a significant 
share of the values of these parameters account 
for day/night HR differences. Besides, careful OT 
evaluation can be performed only in laboratory 
conditions, which is important advantage over the 
24-h Holter ECG monitoring, which is also often 
used for determination of HRV [15].
Statistical analysis
All data were processed using the statistical 
package Statistica 10.0 (Statsoft, Tulsa, Oklahoma, 
USA). Normal distribution of the obtained data was 
confirmed with Shapiro-Wilk’s W-test. Normally 
distributed data is presented as means ± standard 
error mean and abnormally distributed parameters 
(most of the parameters of HRV) as median (quar-
tile range). Nonparametric Mann-Whitney U-test 
was used to compare HRV parameters, c2 test was 
used for qualitative data presented as positive/ 
/negative. In figures, data is presented as mean and 
standard error mean (error bar). If not indicated 
otherwise, p < 0.05 was considered significant.
Results
Anthropometric data
There were 12 (63.2%) male and 7 (36.8%) 
female patients in this study. A control group con-
sisted of 30 apparently healthy subjects of about the 
same age (Table 1) and similar gender distribution 
— 20 (66.7%) males and 10 (33.3%) females, differ-
ence with MS group not significant with p = 0.802 
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(c2 test). Among the 19 MS subjects enrolled in the 
study, 15 have had confirmed FBN1 mutations by 
genetic studies. The data from these 15 patients 
were used for further statistical evaluations. One 
of the patients was excluded from the study since 
frequent ventricular extrasystoles were detected. 
Three remaining patients with clinical evidence 
of MS but without confirmed FBN1 mutation are 
discussed separately below in the text.
The comparison of anthropometric parameters 
of MS and control group is presented in Table 1. 
As it could be expected MS patients are taller and 
relatively slimmer (BMI is lower). These features 
are among the typical characteristics of MS.
HRV in supine position
The parameters of HRV in MS patients were 
found to have a specific pattern — increased HR 
with most of the HRV parameters decreased. HR 
in MS patients was significantly higher than in the 
controls 71.7 vs. 61.9 bpm (p < 0.001, Fig. 1A). 
All the time domain parameters including SDNN, 
RMSSD and pNN50 were found to be signifi-
cantly lower in MS patients (Fig. 1B–D). SDNN 
and RMSSD is decreased roughly 2–3-fold while 
pNN50 (reflecting mostly parasympathetic activ-
ity) decrease was much more profound — almost 
15-fold (Mann-Whitney U-test p < 0.001 in all cases).
The evaluation of the frequency domain HRV 
is also characterized by a dramatic decrease of 
these parameters in MS patients with FBN1 muta-
tions (Fig. 2). TP is 4-fold lower than in the control 
group (p < 0.001).  Interestingly, the decrease of 
VLF, which is usually associated with the activ-
ity of humoral, metabolic and central regulatory 
influences on the heart rhythm, is not so dra-
matic — 2.8-fold (p < 0.001), while LF (associated 
with mostly sympathetic output) decreased 5-fold 
(p < 0.001) and HF (mainly parasympathetic activity) 
decrease was even more profound — 8-fold 
(p < 0.001). Despite such convincing evidence of 
changes in all frequency domain indexes of HRV 
the mean of HF/LF ratio was not significantly dif-
ferent in studied groups — 1.92 vs. 1.84 in MS 
and control group, respectively (p = 0.279, Mann-
-Whitney U-test), mainly due to high variations of 
this parameter within the groups.
Even more interesting seems to be the pattern 
of VLF-LF-HF distribution within the TP in MS 
patients with FBN1 mutation in comparison with 
the control group. While in the control group mean 
values of VLF, LF and HF power are almost equal 
with slight dominance of power of “autonomic” 
regulation (each LF and HF accounts for approxi-
mately 34% of TP), in MS patients, in addition to 
the decrease described above these frequency 
bands striking decrease in their share in TP (29 and 
19% in LF and HF, respectively) was observed. 
Meanwhile the share of VLF in TP increased to 
52% indicating “centralization” (relative increase 
of central nervous system involvement) of heart 
rhythm regulation in MS patients with FBN1 muta-
tions (Fig. 3).
HRV in orthostatic test
In the OT, general characteristics of HRV 
remain similar to those in the supine position; 
however some important peculiarities have been 
revealed. HR increase in response to an active OT 
was similar in both the MS and the control group, 
HR was higher in patients (p = 0.020, Fig. 4A). 
Both SDNN and RMSSD in healthy controls were 
higher than in MS patients, p < 0.001 (Fig. 4B, C). 
However, in the case of pNN50, no significant dif-
ference was found by t-test (p = 0.312, Fig. 4D). 
The later probably is due to relatively high values of 
standard deviation and standard error mean, which 
is a rather technical issue (method limitation) in 
this case. Interestingly, when pNN50 difference 
was compared by Mann-Whitney U-test, the dif-
ference was found to be significant (p < 0.001).
HF waves are naturally suppressed in the or-
thostatic position and activation of LF band which is 
associated with sympathetic activity was observed. 
Absolute values and distribution patterns of other 
frequency domain HRV parameters are very simi-
Table 1. Age and main anthropometric parameters of studied subjects (mean ± standard error).
Parameter Marfan syndrome 
group (n = 18)
Control group  
(n = 30)
P value, t-test
Age [years] 30.7 ± 1.6 29.3 ± 1.0 0.431
Height [cm] 187.3 ± 2.5 178.4 ± 1.1 < 0.001
Weight [kg] 72.8 ± 3.6 78.8 ± 2.4 0.168
Body mass index [kg/m2] 20.6 ± 0.8 24.7 ± 0.7 0.001
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lar to the findings in the supine position (Fig. 5). 
While in the OT of the control group, the value of 
VLF was about the same as LF. In MS patients, as 
was observed in the supine position, VLF waves 
dominated in the spectrum.
HRV in MS patients with normal FBN1 gene
Three patients with the MS phenotype were 
found to have a normal FBN1 gene. It was of 
interest to compare HRV in these patients with 
respective parameters in MS patients. The size 
of the sample was too small for providing sound 
statistical evaluation, however, these data still 
deserve to be described.
Figure 6 shows that all the patients with 
a normal FBN1 gene had higher SDNN values than 
any of the MS patients with the FBN1 mutation. 
SDNN is one of the most general and non-specific 
parameters of HRV and it correlates with many 
other parameters. Hence the mean value in this 
case seems to be much higher than in MS patients 
Figure 1. The values of heart rate (A), and time-domain indices of heart rate variability — standard deviation of normal 
RR intervals (SDNN) (B), square root of the mean squared differences of successive RR intervals (RMSSD) (C), and 
percentage of differences between adjacent normal RR intervals exceeding 50 ms (pNN50) (D) in 15 patients with 
FBN1 mutations and apparently healthy subjects (control group, n = 30) in supine position; MS — Marfan syndrome.
Figure 2. The values of frequency domain parameters 
of heart rate variability (total power [TP], very low fre-
quency [VLF], low frequency [LF] and high frequency 
[HF]) in 15 patients with FBN1 mutations and apparently 
healthy subjects (control group, n = 30) in supine posi-
tion; MS — Marfan syndrome.
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with an FBN1 mutation (about 40 ms compared to 
24 ms), but it is still far below the value of healthy 
controls (59.4 ms).
In the case of spectral (frequency domain) HRV, 
a similar situation was observed (Supplement - 
ary Fig. S1). TP, LF and especially HF in 2 out of 
Figure 3. The absolute values and relative distribution of very low frequency (VLF), low frequency (LF), and high fre-
quency (HF) power in 15 patients with FBN1 mutations (A) and (B) apparently healthy subjects (control group, n = 30) 
in supine position. The values of the parameters (a power of respective band) is expressed in ms2.
Figure 4. The values of heart rate (A), and time-domain indices of heart rate variability — standard deviation of normal 
RR intervals (SDNN) (B), square root of the mean squared differences of successive RR intervals (RMSSD) (C) and per-
centage of differences between adjacent normal RR intervals exceeding 50 ms (pNN50) (D) in 15 patients with FBN1 
mutations and apparently healthy subjects (control group, n = 30) during orthostatic test; MS — Marfan syndrome.
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3 patients without the FBN1 mutation were much 
higher than in MS patients with the FBN1 muta-
tion, while one value was within the range of the 
least group. In case of VLF the trend was the same, 
but the difference was not so evident. These unex-
pected observations are precarious and may not be 
confirmed in further studies. However, this finding 
should not be ignored since it could be important 
for explaining further the possible mechanisms of 
decreased HRV in MS patients.
Discussion
Marfan syndrome has a special clinical pat-
tern with typical “recognizable” anatomical fea-
tures. However, development and availability of 
genetic testing revealed a number of syndromes 
which overlap with MS by clinical manifestations 
but differ by genetic defects. Since the molecular 
mechanism of these diseases is different, it could 
be expected that some of the clinical features and 
outcomes may be different too. This is particularly 
important in the case of serious complications and 
life-threatening conditions like aortic dissection 
and cardiac arrhythmias, because with similar 
clinical features the risk of mortality and serious 
complications could be completely different.
Obtained anthropometric data were usual — 
the height was expectedly higher and consequently 
BMI lower in MS patients compared to the respec-
tive controls. Other parameters were similar in 
both groups. Clinical features of MS were compara-
ble with the data from other authors [16]. However, 
a relatively large number of patients, almost half, 
underwent serious surgery — aortic root/valve-
replacing surgery (Bentall procedure) in the past 
which may increase the severity of MS manifesta-
tions in our cohort. This may indicate that these 
patients have more severe manifestations of MS 
with the development of life threatening complica-
tions requiring surgical correction. Nevertheless, 
Bentall surgery, in particular its modified version, 
is considered reliable and relatively safe. There-
fore, long-term outcomes are rather optimistic 
[2, 17]. In our study, we did not observe substantial 
differences in HRV parameters of MS patients 
with FBN1 mutations after surgery compared to 
those who did not undergo the procedure. The 
distribution of HRV was similar in both subgroups 
and separate analysis has not been performed in 
this study.
The most important cardiovascular concerns 
after aortal dissections and aneurysms in patients 
with MS are ventricular arrhythmias [6]. It is well 
known that decreased HRV is associated with 
numerous health problems including increased all-
cause mortality, ventricular arrhythmia mortality, 
heart failure, diabetes mellitus type 2 risks even 
without evidence of autonomic neuropathy, liver 
damage, hypertension and many other problems 
[8]. There is growing evidence that a decrease in 
HRV eventually may appear not only as a conse-
Figure 5. The values of frequency domain parameters of 
heart rate variability (total power [TP], very low frequen-
cy [VLF], low frequency [LF] and high frequency [HF]) in 
15 patients with FBN1 mutations and apparently healthy 
subjects (control group, n = 30) during orthostatic test; 
MS — Marfan syndrome.
Figure 6. The values of standard deviation of normal 
RR intervals in supine position in patients with (n = 15) 
and without FBN1 mutations (n = 3) in supine position.
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quence of decreased activities of sympathetic and 
parasympathetic branches of autonomic nervous 
system, but also as an independent metabolic 
phenomenon, related to possible impairment of 
cardiomyocytes, especially cells of sinoatrial node 
(SAN) that may be less responsive to the neural 
and humoral impacts [18].
The exact mechanism of HRV suppression 
in MS remains unclear. However, in our opinion, 
there exist at least several possibilities. First, 
a genetic mutation in FBN1 gene leads to changes 
responsible for HRV decrease. To our best knowl-
edge, up to date there has been no experimental 
or clinical evidence of affected neurological func-
tion, especially function of autonomic nervous 
system that may decrease the oscillations of the 
heart rhythm. In MS patients, the TGF-b path-
way is overactivated and that may cause several 
important cardiovascular consequences. Studies 
on the rat model of pressure overload proved 
involvement of TGF-b activation in myocardial 
fibrosis and diastolic dysfunction [5]. Importantly, 
this study has demonstrated that TGF-b function 
blocking resulted in prevention of fibroblast acti-
vation (inhibition of fibrosis) and also prevented 
diastolic dysfunction development. TGF-b might 
suppress HRV by activating inflammatory cas-
cades, affecting endothelial function with inhibited 
nitric oxide release and development of oxidative 
stress [19].
In this study, among the patients with clinically 
diagnosed MS according to revised Ghent criteria, 
15 subjects had confirmed FBN1 mutations. The 
other 3 patients who did not have FBN1 mutations 
were included into a separate small subgroup. 
Despite a low number of patients (only 3), dra-
matic increases in HRV were observed compared 
to patients with a confirmed mutation of FBN1 
(Figs. 6, 7). It would probably be more correct to 
say partially preserved HRV rather than increased, 
considering higher values of HRV in the controls. 
These rather accidental findings indicate that 
FBN1 mutation and malfunction may be specifically 
responsible for HRV suppression in MS patients 
with FBN1 mutations, either directly or indirectly. 
However, the mechanisms that may cause the 
fibrillin 1 negative influence on HRV are unclear. 
First of all, fibrillin 1 is a protein of the extracel-
lular matrix and it is difficult to imagine in what 
way its deranged function may influence activity 
of the autonomic nervous system. Besides, there 
is no evidence that functionally insufficient fibrillin 1 
may affect the electric activities of neurons or 
cardiomyocytes. These observations, considering 
obvious differences between the groups, indicate 
rather indirect effects of this mutation.
An important pathogenic mechanism likely to 
be indirectly involved is an increased concentra-
tion of TGF-b as a result of altered binding to the 
defective fibrillin 1 protein [1, 2]. TGF-b, as shown 
in numerous studies, is responsible for vascular 
dysfunction and oxidative stress [19], myocardial 
fibrosis, diastolic dysfunction and other cardio-
vascular alterations [2, 4, 5]. The second possible 
mechanism of HRV suppression derives from the 
study of affected skeletal muscle function in MS 
patients. The decreased efficiency of an energy 
supply within the muscle cells was documented 
[20]. The study of biventricular dysfunction in MS 
by cardiac magnetic resonance revealed that it is 
an intrinsic feature not related to aortic elasticity 
or b-blocker usage [21]. This means that a specific 
problem of heart functioning, probably of metabolic 
nature exists in MS. This raises the other impor-
tant suggestion that the HRV suppression is likely 
be due to the problems in intrinsic excitability and 
deranged properties of the SAN and its cells rather 
than suppressed autonomic regulation. Similarly, 
as in skeletal muscles, affected electrical activity 
and metabolic efficiency in the SAN cells may sup-
press their ability to respond to the external regu-
latory signals. We suggest that the amplitude of 
the heart rhythm oscillations will be higher when 
the adenosine thriphosphate (ATP) concentration 
in the cells is higher. More profound hyperpolari-
zation of cell membrane and consequently lower 
amplitude is expected in conditions of metabolic 
problems such as low ATP supply due to acute or 
chronic hypoxia, derangements of redox potential 
and signaling [18].
The third possibility is that the decrease in 
HRV appears as a consequence of unspecific dis-
ease advancement. Chronic persistence of defec-
tive fibrillin 1 protein accompanied by the activation 
of TGF-b pathway could lead to the chronic micro- 
and macrovascular dysfunction [19], gradual de-
crease in tissue perfusion efficiency, development 
of hypoxia and therefore increase in sympathetic 
activity, and consecutively elevation of HR. This 
possibility is also supported by the increased sus-
ceptibility of MS patients to the serious ventricular 
rhythm disorders including ventricular fibrillation. 
Low HRV is also known to be a risk factor for fatal 
ventricular arrhythmias, especially in case of myo-
cardial infarction [8]. The medium for this seems 
to be local hypoxia and lack of ATP synthesis and 
respective energy supply for maintaining sufficient 
membrane potential of cardiac cells.
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Finally, the fourth possible mechanism of HRV 
suppression arises from the recent indications of 
oxidative stress development in MS patients [19]. 
A relatively simple mouse model, as well as cohort 
human study clearly showed the evidence of accu-
mulation of carbonyl protein modification products 
in human serum and isoprostane accumulation and 
low superoxide dismutase expression in mouse 
model. The patients with the diseases typically 
considered to be associated with oxidative stress 
usually have severely impaired HRV. This does 
not seem to be a coincidence since this association 
is overwhelming, however the explanations and 
cause-consequence relationships remain largely 
unclear. In fact, there have been a few recent at-
tempts to solve this puzzle, yetr the authors could 
not provide sufficient evidence and theoretical 
background for the explanation of this phenomenon 
[22]. As we have recently hypothesized [18], the 
interpretation of decreased HRV may not be simply 
limited to an autonomic dysfunction and increased 
sympathetic tone. The negative correlations of 
HRV parameters with weight, visceral fat, BMI, 
and a number of carbohydrate metabolism param-
eters in apparently healthy sedentary subjects 
also confirm this hypothesis [23]. The energetic 
deficiency as well as chronic hypoxia and persis-
tence of oxidative stress seem to play major roles 
in HRV suppression in MS patients. In real life, 
all mentioned mechanisms plausibly contribute to 
HRV suppression in MS patients with FBN1 gene 
mutations. All these processes, to some extent, 
take place in the organism of patients and HRV 
decrease reflects the degree of metabolic derange-
ments and heart tissue damage. The growing inter-
est in HRV as the prognostic and risk stratification 
marker for cardiovascular diseases also appears to 
be important for MS [12]. Moreover, monitoring of 
HRV for a follow-up observation of disease progres-
sion could serve as a sensitive indicator reflecting 
dynamics of treatment efficiency [15].
Limitations of the study
The limitations of our study arise mainly from 
the relatively small cohort of patients recruited. 
Almost a half of the patients were post-surgery 
which means that they were at an advanced stage 
of the disease. However, the remaining patients 
also were not in the condition of good health. Some 
of the patients before participation in the study 
did not take losartan as a preventive medicine 
and were recommended to start the treatment 
as soon as possible. A larger number of patients 
with the MS phenotype but with a normal FBN1 
gene could also improve the quality of the study. 
The measurement of plasma levels of TGF-b and 
determination of possible correlations with HRV 
parameters may add important information for 
analysis and interpretation of mechanistic relation-
ships. Nevertheless, statistical evaluation revealed 
convincing differences in the HRV between MS 
patients with FBN1 mutations and healthy controls, 
thus confirming these substantial changes point out 
potential clinical implications.
Conclusions
A marked decrease of HRV, documented in the 
study, may be an important clinical feature in MS 
patients with confirmed FBN1 gene mutations. Its 
potential role as a marker of disease severity and 
increased risk of mortality, independent of surgical 
issues, requires further careful evaluation.
Highlights
1. Marfan syndrome patients with FBN1 muta-
tion have decreased HRV.
2. The reduction of HRV was observed for both 
time- and frequency-domain indices.
3. HRV decrease is likely to be caused by bio-
chemical effects of defective fibrillin 1 protein.
4. Low HRV may contribute to the severity of the 
disease independent of vascular complications.
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Supplementary Figure S1. The values of frequency domain parameters of heart rate variability: total power (TP) (A), 
very low frequency (VLF) (B), low frequency (LF) (C) and high frequency (HF) (D) in patients with (n = 15) and without 
FBN1 mutations (n = 3) in supine position.
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